LISELLET MORIN: Open Payments
NPI 1053615237 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 25 payments from 9 companies in 2025. Trend: 2023 $490 · 2024 $1,082 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $252 |
| Novartis Pharmaceuticals Corporation | 6 | $151 |
| Lilly USA, LLC | 5 | $107 |
| Daiichi Sankyo Inc. | 2 | $57 |
| Pharmacosmos Therapeutics Inc. | 2 | $41 |
| Gilead Sciences, Inc. | 1 | $34 |
| Caris MPI, Inc. | 1 | $25 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| PFIZER INC. | 1 | $21 |
Products named: ENHERTU, VERZENIO, Fabhalta, KISQALI, MONOFERRIC, INJECTAFER, MI CANCER SEEK, KEYTRUDA.
Industry payments across FL — which companies pay providers there.
